000084204 001__ 84204
000084204 005__ 20200513005822.0
000084204 0247_ $$2doi$$a10.1016/j.addr.2018.10.004
000084204 0248_ $$2sideral$$a108564
000084204 037__ $$aART-2018-108564
000084204 041__ $$aeng
000084204 100__ $$0(orcid)0000-0002-2861-2469$$aMoros, M.$$uUniversidad de Zaragoza
000084204 245__ $$aTriggering antitumoural drug release and gene expression by magnetic hyperthermia
000084204 260__ $$c2018
000084204 5060_ $$aAccess copy available to the general public$$fUnrestricted
000084204 5203_ $$aMagnetic nanoparticles (MNPs) are promising tools for a wide array of biomedical applications. One of their most outstanding properties is the ability to generate heat when exposed to alternating magnetic fields, usually exploited in magnetic hyperthermia therapy of cancer. In this contribution, we provide a critical review of the use of MNPs and magnetic hyperthermia as drug release and gene expression triggers for cancer therapy. Several strategies for the release of chemotherapeutic drugs from thermo-responsive matrices are discussed, providing representative examples of their application at different levels (from proof of concept to in vivo applications). The potential of magnetic hyperthermia to promote in situ expression of therapeutic genes using vectors that contain heat-responsive promoters is also reviewed in the context of cancer gene therapy.
000084204 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/RYC-2014-15512$$9info:eu-repo/grantAgreement/ES/MINECO/RYC-2015-17640
000084204 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000084204 590__ $$a15.519$$b2018
000084204 591__ $$aPHARMACOLOGY & PHARMACY$$b3 / 266 = 0.011$$c2018$$dQ1$$eT1
000084204 592__ $$a4.163$$b2018
000084204 593__ $$aPharmaceutical Science$$c2018$$dQ1
000084204 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000084204 700__ $$0(orcid)0000-0002-3373-9341$$aIdiago-López, J.
000084204 700__ $$0(orcid)0000-0003-0641-3407$$aAsín, L.$$uUniversidad de Zaragoza
000084204 700__ $$0(orcid)0000-0002-8223-3267$$aMoreno-Antolín, E.
000084204 700__ $$0(orcid)0000-0003-4516-8694$$aBeola, L.
000084204 700__ $$0(orcid)0000-0001-6170-4237$$aGrazú, V.$$uUniversidad de Zaragoza
000084204 700__ $$0(orcid)0000-0001-5559-8757$$aFratila, R.M.
000084204 700__ $$0(orcid)0000-0003-2366-3598$$aGutiérrez, L.$$uUniversidad de Zaragoza
000084204 700__ $$0(orcid)0000-0003-1081-8482$$ade la Fuente, J.M.$$uUniversidad de Zaragoza
000084204 7102_ $$12009$$2750$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cÁrea Química Analítica
000084204 7102_ $$12013$$2765$$aUniversidad de Zaragoza$$bDpto. Química Orgánica$$cÁrea Química Orgánica
000084204 773__ $$g138 (2018), 326 - 343$$pAdv. drug deliv. rev.$$tADVANCED DRUG DELIVERY REVIEWS$$x0169-409X
000084204 8564_ $$s703154$$uhttps://zaguan.unizar.es/record/84204/files/texto_completo.pdf$$yPostprint
000084204 8564_ $$s38826$$uhttps://zaguan.unizar.es/record/84204/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000084204 909CO $$ooai:zaguan.unizar.es:84204$$particulos$$pdriver
000084204 951__ $$a2020-05-13-00:50:21
000084204 980__ $$aARTICLE